[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598691":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":135,"collaborators":137,"id":141,"slug":142,"hasResults":143,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":143,"sex":149,"minAge":150,"maxAge":10,"enrollmentInfo":151,"targetDuration":10,"studyType":154,"phases":10,"briefSummary":155,"conditions":156,"keywords":10,"overallStatus":158,"whyStopped":10,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Association for Innovation and Biomedical Research on Light and Image","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Control Group (Non-Prostaglandin IOP-lowering compound)",null,"750 eyes treated with intraocular pressure-lowering compounds that do not belong to the prostaglandin analogue class. These treatments may include beta-adrenergic blocking agents (e.g., timolol, betaxolol), carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide), alpha-2 adrenergic agonists (e.g., brimonidine) or rho kinase inhibitors (e.g., netarsudil).",{"label":13,"type":10,"description":14,"interventionNames":10},"Interventional group (prostaglandin analogues)","750 eyes treated with any prostaglandin analogue, such as latanoprost (e.g., Xalatan® 50 µg\u002FmL, Pfizer), travoprost, tafluprost, bimatoprost, or unoprostone.",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Ana S Silva, PhD","CONTACT","+351239480112","neuropa@aibili.pt",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Liliana C Soares, MsC","+351239480105","lcarvalho@aibili.pt",[26,40,51,64,75,85,93,106,116,127],{"facility":27,"status":10,"city":28,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Department of Ophthalmology University of Bonn","Bonn","Germany","DE",{"type":32,"coordinates":33},"Point",[34,35],7.09549,50.73438,{"lat":35,"lon":34},[38],{"name":39,"role":18,"phone":10,"phoneExt":10,"email":10},"Karl Mercieca",{"facility":41,"status":10,"city":42,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"University Eye Hospital Leipzig","Leipzig",{"type":32,"coordinates":44},[45,46],12.37129,51.33962,{"lat":46,"lon":45},[49],{"name":50,"role":18,"phone":10,"phoneExt":10,"email":10},"Jan Darius Unterlauff",{"facility":52,"status":10,"city":53,"state":10,"zip":10,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Centre for Clinical Trials at San Paolo Hospital University of Milan","Milan","Italy","IT",{"type":32,"coordinates":57},[58,59],9.18951,45.46427,{"lat":59,"lon":58},[62],{"name":63,"role":18,"phone":10,"phoneExt":10,"email":10},"Luca Rossetti",{"facility":65,"status":10,"city":66,"state":10,"zip":10,"country":54,"countryCode":55,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Eye Unit, University Hospital Maggiore della Carità","Novara",{"type":32,"coordinates":68},[69,70],8.62118,45.44694,{"lat":70,"lon":69},[73],{"name":74,"role":18,"phone":10,"phoneExt":10,"email":10},"Alessandro Rabiolo",{"facility":76,"status":10,"city":77,"state":10,"zip":10,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":84,"contacts":10},"Centro de Oftalmologia Barraquer","Barcelona","Spain","ES",{"type":32,"coordinates":81},[82,83],2.15899,41.38879,{"lat":83,"lon":82},{"facility":86,"status":10,"city":77,"state":10,"zip":10,"country":78,"countryCode":79,"cosmosGeoPoint":87,"geoPoint":89,"contacts":90},"Retina Unit, Department of Ophthalmology, Bellvitge University Hospital",{"type":32,"coordinates":88},[82,83],{"lat":83,"lon":82},[91],{"name":92,"role":18,"phone":10,"phoneExt":10,"email":10},"Silvia S Moreno",{"facility":94,"status":10,"city":95,"state":10,"zip":10,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"University Hospital Basel","Basel","Switzerland","CH",{"type":32,"coordinates":99},[100,101],7.57327,47.55839,{"lat":101,"lon":100},[104],{"name":105,"role":18,"phone":10,"phoneExt":10,"email":10},"Tim J Enz",{"facility":107,"status":10,"city":108,"state":10,"zip":10,"country":109,"countryCode":110,"cosmosGeoPoint":111,"geoPoint":115,"contacts":10},"Clinical Eye Research Centre - St. Paul's Eye Unit, Royal Liverpool University Hospital","Liverpool","United Kingdom","UK",{"type":32,"coordinates":112},[113,114],-2.97794,53.41058,{"lat":114,"lon":113},{"facility":117,"status":10,"city":118,"state":10,"zip":10,"country":109,"countryCode":110,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"ICORG - Imperial College Ophthalmologic Research Group","London",{"type":32,"coordinates":120},[121,122],-0.12574,51.50853,{"lat":122,"lon":121},[125],{"name":126,"role":18,"phone":10,"phoneExt":10,"email":10},"Eduardo Normando",{"facility":128,"status":10,"city":118,"state":10,"zip":10,"country":109,"countryCode":110,"cosmosGeoPoint":129,"geoPoint":131,"contacts":132},"NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust",{"type":32,"coordinates":130},[121,122],{"lat":122,"lon":121},[133],{"name":134,"role":18,"phone":10,"phoneExt":10,"email":10},"HARI JAYARAM",{"type":136,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[138],{"name":139,"class":140},"European Vision Institute Clinical Research Network","NETWORK","100598691","retinal-ganglion-cell-neuroprotection-under-prostaglandin-analogues-100598691",false,"NCT07074782","Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues: NEUROPA - a Retrospective Cohort Study","NEUROPA","Inclusion Criteria:\n\n* Age 18+ years\n* Established glaucoma diagnosis (primary open-angle glaucoma, normal tension Glaucoma, pseudoexfoliation glaucoma, pigmentary dispersion glaucoma) in either eye\n* Visual field mean deviation (MD; location-weighted mean difference from average age-corrected visual field sensitivity) of 2 visual fields differing by no more than 3 dB, for a mean deviation of better than -6.0 dB, or by no more than 4 dB, for a mean deviation worse than -6.0 dB, as measured using Humphrey perimetry (or equivalent Haag-Streit \u002F Octopus; in at least one eye; analogous to The United Kingdom Glaucoma Treatment Study)\n* Treatment with either prostaglandin analogues only or another topically applied IOP-lowering compound only for at least 3 years\n* Documented follow-up period of at least 3 years\n* At least 6 patient visits documented over the follow-up period with readings of IOP, visual field, OCT\n* No additional glaucoma intervention apart from laser trabeculoplasty and\u002For cataract surgery during the observational period\n\nExclusion Criteria:\n\n* Follow-up period \\\u003C 3 years\n* Number of patient visits \\\u003C6 visits\n* Number of OCT, visual field readings during the observation period \\\u003C 6\n* Low compliance\u002Ftherapy interruption\n* Beginning of combination therapy of prostaglandin analogues and other IOP lowering eye drops during the observation period\n* In case of glaucoma diagnosis in both eyes: different topical IOP-lowering treatment regimes (e.g. prostaglandin analogues in one eye and beta-adrenergic blocking agents in the fellow eye)\n* Additional glaucoma intervention during the observational period other than laser trabeculoplasty and\u002For cataract surgery","ALL","18 Years",{"count":152,"type":153},1500,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate whether prostaglandin analogue eye drops have a direct neuroprotective effect on retinal ganglion cells - beyond their intraocular pressure (IOP)-lowering effect - in adult patients with glaucoma or ocular hypertension. The study includes individuals diagnosed with glaucoma (any sex\u002Fgender, adult age groups) undergoing standard clinical treatment. The main questions it aims to answer are:\n\n* Do prostaglandin analogues provide a neuroprotective effect on retinal ganglion cells that is independent of their IOP-lowering properties?\n* Should prostaglandin analogues be promoted\u002Ffavoured over other IOP-lowering compounds for long-term glaucoma management?\n\nResearchers will compare an interventional group, which consist of 750 eyes treated with prostaglandin analogues (e.g., latanoprost, travoprost, tafluprost, bimatoprost, unoprostone), with a control group, which consist of 750 eyes treated with non-prostaglandin IOP-lowering compounds (e.g., timolol, dorzolamide, brimonidine, netarsudil) to see if treatment with prostaglandin analogues is associated with better retinal ganglion cell survival over a period of 3 years (36 months).\n\nData will be collected from individuals who had at least 36 months of documented follow-up, with clinical data available at approximately 3, 6, 12, 24, and 36 months. Eligible individuals must have been treated with either prostaglandin analogues or other intraocular pressure (IOP)-lowering agents as part of routine clinical care. The data to be obtained from medical records will include at least:\n\n* Intraocular pressure readings\n* Visual field testing\n* OCT measures\n* Visual acuity\n* Adverse events\n* Treatment adherence\u002Fcompliance\n* Additional glaucoma interventions",[157],"Glaucoma","NOT_YET_RECRUITING","2026-05-05",{"date":161,"type":162},"2026-05-06","ACTUAL",{"date":164,"type":153},"2026-05",{"date":166,"type":153},"2026-06",{"name":5,"class":6},10]